This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shea, S. Articles by Goldman, L. Search for Related Content PubMed PubMed Citation Articles by Shea, S. Articles by Goldman, L.

Circulation, Vol 71, 22-30, Copyright © 1985 by American Heart Association

ARTICLES

Treatment of hypertension and its effect on cardiovascular risk factors: data from the Framingham Heart Study

S Shea, EF Cook, WB Kannel and L Goldman

Analysis of the Framingham Heart Study experience between 1958 and 1970 showed a progressive increase in the rate of treatment and control of hypertension. With cross-sectional criteria to define diastolic hypertension, the treatment rate rose from 35% in 1958 through 1960 to 69% in 1968 through 1970 (p less than .001), and the treatment rate for sustained hypertension rose from 55% in 1958 through 1960 to 85% in 1968 through 1970 (p less than .001). Treated hypertensive subjects had higher pretreatment values of blood pressure but not of other cardiovascular risk factors than untreated hypertensive subjects. Treatment was more successful in controlling hypertension in later years (p less than .001), but in all years treatment reduced systolic and diastolic blood pressure without causing significant changes in mean serum cholesterol or glucose levels. In treated hypertensive subjects, the 8 year predicted risk of coronary heart disease declined by 2.3 events per 100 people compared with that in untreated hypertensive subjects (p less than .0001). The observed incidence of coronary heart disease was consistent with these predictions and suggested that treatment may be especially beneficial in subjects who have systolic blood pressures of 180 mm Hg or higher and who are treated for more than 2 successive years.

This article has been cited by other articles:

				D. F. Terry, M. A. Wilcox, M. A. McCormick, and T. T. Perls Cardiovascular Disease Delay in Centenarian Offspring J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2004; 59(4): M385 - M389. [Abstract] [Full Text] [PDF]

				R. J. Johnson, K. R. Tuttle, B. Culleton, and D. Levy Much Ado About Nothing, or Much to Do About Something? The Continuing Controversy Over the Role of Uric Acid in Cardiovascular Disease Hypertension, March 1, 2000; 35 (3): e10 - e10. [Full Text]

				S. M. Grundy, G. J. Balady, M. H. Criqui, G. Fletcher, P. Greenland, L. F. Hiratzka, N. Houston-Miller, P. Kris-Etherton, H. M. Krumholz, J. LaRosa, et al. Primary Prevention of Coronary Heart Disease: Guidance From Framingham : A Statement for Healthcare Professionals From the AHA Task Force on Risk Reduction Circulation, May 19, 1998; 97(18): 1876 - 1887. [Full Text] [PDF]

				P. A. Sytkowski, R. B. D'Agostino, A. J. Belanger, and W. B. Kannel Secular Trends in Long-term Sustained Hypertension, Long-term Treatment, and Cardiovascular Mortality : The Framingham Heart Study 1950 to 1990 Circulation, February 15, 1996; 93(4): 697 - 703. [Abstract] [Full Text]

				D. Blecker Antihypertensive Therapy with Isradipine in Patients with Special Safety Concerns Angiology, December 1, 1994; 45(12): 997 - 1008. [Abstract] [PDF]